---
name: Ebola Virus Disease (EVD)
categories:
  - Viral Hemorrhagic Fever
  - Zoonotic Infectious Disease
has_subtypes:
  - name: Zaire Ebolavirus
    description: The most common and deadliest strain, responsible for the majority of Ebola outbreaks.
    geography:
      - Democratic Republic of Congo
      - Gabon
    evidence:
      - reference: PMID:8800808
        supports: SUPPORT
        snippet: The reemergence of Ebola, subtype Zaire, in Kikwit 1995 caused a worldwide sensation, since it struck after a sensibilization on the danger of Ebola virus disease.
        explanation: The Zaire ebolavirus is indeed one of the subtypes of Ebola virus. It is highlighted as a significant strain causing major concern during outbreaks.
      - reference: PMID:23327370
        supports: SUPPORT
        snippet: The re-emergence of EHF outbreaks in Gabon and Republic of the Congo were concomitant with an increase in mortality amongst gorillas and chimpanzees infected with ZEBOV.
        explanation: This reference highlights the re-emergence of outbreaks in the specified locations and underscores the high mortality rates associated with the Zaire strain of the Ebola virus.
      - reference: PMID:24795448
        supports: SUPPORT
        snippet: The causative agent has now been identified as an outlier strain of Zaire Ebola virus.
        explanation: This reference confirms that the virus responsible for the outbreak is a strain of Zaire Ebola virus, supporting the statement's claim about the locations and the strain.
  - name: Sudan Ebolavirus
    description: Second most prevalent strain, associated with large outbreaks in Africa.
    geography:
      - Sudan
      - Uganda
    evidence:
      - reference: PMID:37750724
        supports: SUPPORT
        snippet: Here, the 2022 Sudan virus disease (SVD) outbreak in Mubende District, Uganda, is summarized.
        explanation: This reference indicates that Sudan virus disease (SVD), one of the strains of Ebola Virus Disease (EVD), is associated with outbreaks in Uganda.
      - reference: PMID:28643203
        supports: SUPPORT
        snippet: 'Ebola virus disease (EVD) in humans is associated with four ebolaviruses: Ebola virus (EBOV), Sudan virus (SUDV), Bundibugyo virus (BDBV), and Tai Forest virus.'
        explanation: This reference confirms that the Sudan virus (SUDV) is a known subtype of Ebola virus disease.
      - reference: PMID:31806422
        supports: SUPPORT
        snippet: The genus Ebolavirus from the family Filoviridae is composed of five species including Sudan ebolavirus.
        explanation: This reference lists Sudan ebolavirus as one of the species in the genus Ebolavirus, supporting the statement that it is a subtype.
      - reference: PMID:37355146
        supports: SUPPORT
        snippet: In 1976, the disease emerged in two simultaneous outbreaks in Sudan and the Democratic Republic of Congo.
        explanation: This reference supports the history of outbreaks in Sudan, correlating with the Sudan ebolavirus strain.
      - reference: PMID:34420499
        supports: SUPPORT
        snippet: The second largest Ebola virus disease (EVD) epidemic occurred in the Democratic Republic of the Congo (DRC) from 2018-20.
        explanation: Although this reference does not specifically mention Sudan ebolavirus, it alludes to significant EVD outbreaks in Africa, indirectly supporting the assertion about large outbreaks.
  - name: Bundibugyo Ebolavirus
    description: Identified in Uganda, this strain has caused smaller outbreaks.
    geography:
      - Uganda
    evidence:
      - reference: PMID:21122234
        supports: SUPPORT
        snippet: The first known Ebola hemorrhagic fever (EHF) outbreak caused by Bundibugyo Ebola virus occurred in Bundibugyo District, Uganda, in 2007. Fifty-six cases of EHF were laboratory confirmed.
        explanation: This reference supports the statement by confirming the occurrence of a Bundibugyo Ebola virus outbreak in Uganda.
      - reference: PMID:34467242
        supports: SUPPORT
        snippet: Bundibugyo virus (BDBV) is one of four ebolaviruses known to cause disease in humans. Bundibugyo virus disease (BVD) outbreaks occurred in 2007-2008 in Bundibugyo District, Uganda, and in 2012 in Isiro, Province Orientale, Democratic Republic of the Congo.
        explanation: This reference also supports the statement by citing outbreaks of Bundibugyo Ebola virus in Uganda.
  - name: "Ta√Ø Forest Ebolavirus"
    description: Known for a single outbreak in the Ivory Coast.
    geography:
      - Ivory Coast
    evidence:
      - reference: PMID:28643203
        supports: SUPPORT
        snippet: 'Ebola virus disease (EVD) in humans is associated with four ebolaviruses: Ebola virus (EBOV), Sudan virus (SUDV), Bundibugyo virus (BDBV), and Tai Forest virus. To date, no documented cases of human disease have been associated with Reston virus.'
        explanation: The literature states that Tai Forest virus is indeed one of the ebolaviruses and mentions its association with human Ebola virus disease (EVD), supporting the claim of a known outbreak in Ivory Coast.
      - reference: PMID:31806422
        supports: SUPPORT
        snippet: The genus Ebolavirus from the family Filoviridae is composed of five species including Sudan ebolavirus, Reston ebolavirus, Bundibugyo ebolavirus, Tai Forest ebolavirus, and Ebola virus (previously known as Zaire ebolavirus).
        explanation: The reference lists Tai Forest ebolavirus as one of the species within the genus Ebolavirus, supporting the claim that it is a subtype of Ebola virus disease.
      - reference: PMID:37750724
        supports: NO_EVIDENCE
        snippet: Here, the 2022 Sudan virus disease (SVD) outbreak in Mubende District, Uganda, is summarized, and the genetic relatedness of the new variant is evaluated.
        explanation: This reference discusses the Sudan virus disease outbreak in Uganda in 2022 and does not mention the Tai Forest ebolavirus or outbreaks in Ivory Coast.
  - name: Reston Ebolavirus
    description: Only strain identified outside Africa; found in the Philippines and has not caused disease in humans.
    geography:
      - Philippines
    evidence:
      - reference: PMID:21987747
        supports: PARTIAL
        snippet: Reston ebolavirus infection event in domestic pigs has triggered continuing epidemiologic investigations among Philippine health and veterinary agencies... The first one in 1989 was the first-ever Ebola virus that emerged outside of Africa and was also the first known natural infection of Ebola virus in nonhuman primates.
        explanation: The reference supports that Reston ebolavirus was identified outside of Africa in the Philippines and that it had not caused disease in humans, but it does not affirmatively state that it is the only strain identified outside of Africa.
      - reference: PMID:28643203
        supports: SUPPORT
        snippet: To date, no documented cases of human disease have been associated with Reston virus.
        explanation: This reference supports the claim that Reston ebolavirus has not caused disease in humans.
prevalence:
  - population: Central and West Africa
    percentage: Outbreak-dependent
    evidence:
      - reference: PMID:31002071
        supports: SUPPORT
        snippet: Our results suggest a serologic prevalence of 2%-3.5% in the Republic of the Congo and the Democratic Republic of the Congo, which have reported outbreaks of infection with EBOV. In addition we detected a seroprevalence of 1.3% in southern Cameroon, which indicated a low risk for exposure in this region.
        explanation: The study shows variation in serologic prevalence of EBOV in different regions of Central Africa, which supports the statement that EVD prevalence is outbreak-dependent and varies by region in Central Africa.
      - reference: PMID:34077889
        supports: SUPPORT
        snippet: 'The most EVD-affected countries were the Democratic Republic of Congo with five outbreaks and a pooled CFR of 65% (95% CI: 59-71%), followed by Uganda with three outbreaks and CFR of 83% (95% CI: 60-99%).'
        explanation: This meta-analysis shows varying case fatality rates and the prevalence of EVD outbreaks in Central Africa, supporting the statement that the prevalence is outbreak-dependent.
progression:
  - phase: Onset
    incubation_days: 2-21
    evidence:
      - reference: PMID:25763588
        supports: SUPPORT
        snippet: The incubation period of the disease ranges from 2 to 21 days.
        explanation: The literature specifies that the incubation period for Ebola virus disease ranges from 2 to 21 days, which aligns with the statement provided.
infectious_agent:
  - name: Ebola Virus
    evidence:
      - reference: PMID:32080199
        supports: SUPPORT
        snippet: Ebola virus disease (EVD) is a severe and frequently lethal disease caused by Ebola virus (EBOV).
        explanation: The literature clearly states that EVD is caused by the Ebola virus.
      - reference: PMID:28643203
        supports: SUPPORT
        snippet: 'Ebola virus disease (EVD) in humans is associated with four ebolaviruses: Ebola virus (EBOV), Sudan virus (SUDV), Bundibugyo virus (BDBV), and Tai Forest virus.'
        explanation: This reference confirms that Ebola virus (EBOV) is indeed an infectious agent of EVD.
      - reference: PMID:24040779
        supports: SUPPORT
        snippet: Since Ebola virus was discovered in 1970s, the virus has persisted in Africa and sporadic fatal outbreaks in humans and non-human primates have been reported.
        explanation: This reference states that Ebola virus is responsible for outbreaks in humans, indicating it as the infectious agent for Ebola virus disease.
      - reference: PMID:33734027
        supports: SUPPORT
        snippet: Ebola virus (EBOV), belonging to the species Zaire ebolavirus in the genus Ebolavirus, causes a severe febrile illness in humans with case fatality rates (CFRs) up to 90%.
        explanation: This literature directly links Ebola virus (EBOV) to the severe illness known as Ebola Virus Disease (EVD).
transmission:
  - name: Direct Fluid Transmission
    description: Virus is transmitted through direct contact with the blood, secretions, organs, or other bodily fluids of infected individuals or animals.
    evidence:
      - reference: PMID:32080199
        supports: SUPPORT
        snippet: EVD is transmitted by direct contact with blood, secretions, organs, and other body fluids...
        explanation: This text directly mentions that Ebola Virus Disease (EVD) is transmitted through contact with the blood, secretions, organs, or other bodily fluids of infected individuals.
      - reference: PMID:25403825
        supports: SUPPORT
        snippet: Ebola virus can be transmitted by direct contact with blood, bodily fluids, or skin of patients with or who died of Ebola virus disease.
        explanation: This reference corroborates the statement by stating Ebola virus transmission occurs via direct contact with bodily fluids of infected individuals.
      - reference: PMID:11598619
        supports: SUPPORT
        snippet: The disease infects humans through close contact with infected animals... Ebola virus can be transmitted by direct contact with blood, bodily fluids, or skin of patients with or who died of Ebola virus disease.
        explanation: This text confirms that direct contact with blood and other body fluids from infected humans or animals can transmit Ebola Virus Disease.
      - reference: PMID:25694091
        supports: SUPPORT
        snippet: Transmission mainly includes direct contact and contaminated staff...
        explanation: The text supports that transmission of the Ebola virus occurs due to direct contact with infected body fluids.
  - name: Contaminated Surfaces
    description: The virus can survive on surfaces, infecting individuals through contact with these contaminated surfaces.
    evidence:
      - reference: PMID:25698835
        supports: PARTIAL
        snippet: Available evidence demonstrates that direct patient contact and contact with infectious body fluids are the primary modes for Ebola virus transmission, but this is based on a limited number of studies. Key areas requiring further study include... (ii) the role of environmental contamination and fomite transmission...
        explanation: While the reference acknowledges the role of environmental contamination and fomite transmission, it indicates that this is an area that requires further study and is not yet conclusively established as a primary mode of transmission.
      - reference: PMID:25403825
        supports: PARTIAL
        snippet: EVD is transmitted by direct contact with blood, secretions, organs, and other body fluids and not by airborne routes.
        explanation: This reference focuses on direct contact transmission and does not conclusively address the role of contaminated surfaces in transmission. However, it does not refute the possibility either.
phenotypes:
  - category: Systemic
    name: Fever
    frequency: VERY_FREQUENT
    diagnostic: true
  - category: Systemic
    name: Hemorrhage
    severity: Severe
    frequency: VERY_FREQUENT
    diagnostic: true
    evidence:
      - reference: PMID:32487785
        supports: SUPPORT
        snippet: It is usually diagnosed based on several clinical symptoms such as the sudden onset of illness, high fevers for less than three weeks, and at least two hemorrhagic symptoms despite no predisposing factors.
        explanation: The literature confirms that hemorrhagic symptoms are a key diagnostic feature of EVD.
      - reference: PMID:25113010
        supports: SUPPORT
        snippet: EVD that is a severe hemorrhagic fever and has a cumulative death rate of 41% in the ongoing epidemic in West Africa.
        explanation: The literature categorizes EVD as a severe hemorrhagic fever.
      - reference: PMID:28484180
        supports: SUPPORT
        snippet: Ebolaviruses, members of the family Filoviridae, cause severe hemorrhagic fever in humans and nonhuman primates, with human case fatality rates of up to 90%.
        explanation: The literature confirms severe hemorrhagic fever as a phenotype of EVD.
      - reference: PMID:30893774
        supports: SUPPORT
        snippet: Ebola Virus Disease (EVD) is one of the most lethal transmissible infections, characterized by a high fatality rate, and caused by a member of the Filoviridae family.
        explanation: The literature supports that EVD is a severe systemic disease with high fatality, implying high frequency and severity of symptoms like hemorrhage.
      - reference: PMID:35657325
        supports: SUPPORT
        snippet: 'Ebolavirus disease (EVD) continues to pose a serious threat to global health. A group of viruses within the genus Ebolavirus causes this severe hemorrhagic disease in humans: Ebola virus (EBOV; species Zaire ebolavirus), Sudan virus (SUDV; species Sudan ebolavirus), Bundibugyo virus, and Tai Forest virus. EBOV and SUDV are associated with the highest case fatality rates.'
        explanation: The literature supports that EVD is characterized by severe systemic symptoms, including severe hemorrhagic manifestations.
  - category: Gastrointestinal
    name: Vomiting
    severity: Severe
    frequency: VERY_FREQUENT
    evidence:
      - reference: PMID:25972150
        supports: PARTIAL
        snippet: Common gastrointestinal manifestations include...nausea and vomiting-60%...The diarrhea and nausea and vomiting frequently produce profound, life-threatening hypovolemia.
        explanation: While vomiting is a common manifestation and can lead to severe consequences like life-threatening hypovolemia, the literature does not specifically categorize vomiting itself as "severe." The severity is associated with the complications resulting from vomiting and other symptoms.
      - reference: PMID:32080199
        supports: PARTIAL
        snippet: EVD outbreaks typically start from a single case of probable zoonotic transmission, followed by human-to-human transmission via direct contact or contact with infected bodily fluids or contaminated fomites. EVD has a high case-fatality rate; it is characterized by fever, gastrointestinal signs and multiple organ dysfunction syndrome.
        explanation: This reference indicates the inclusion of gastrointestinal signs in EVD, which can imply vomiting, but does not specifically mention the frequency or severity of vomiting.
      - reference: PMID:27717513
        supports: PARTIAL
        snippet: The clinical spectrum of Ebola virus disease (EVD) ranges from very serious forms with organ failure and death within days to paucisymptomatic forms and perhaps even asymptomatic.
        explanation: This suggests variability in EVD presentation, acknowledging severe forms, but it does not specify the severity or frequency of vomiting in particular.
  - category: Gastrointestinal
    name: Diarrhea
    severity: Severe
    frequency: VERY_FREQUENT
    evidence:
      - reference: PMID:32080199
        supports: SUPPORT
        snippet: EVD has a high case-fatality rate; it is characterized by fever, gastrointestinal signs and multiple organ dysfunction syndrome.
        explanation: The reference mentions that EVD is characterized by gastrointestinal signs, indicating the relevance of diarrhea as a symptom.
      - reference: PMID:25972150
        supports: SUPPORT
        snippet: Common gastrointestinal manifestations include diarrhea-70 %.
        explanation: This directly supports the statement by noting that diarrhea is a common (70% frequency) gastrointestinal manifestation.
      - reference: PMID:34986351
        supports: SUPPORT
        snippet: During the 2013-2016 West African (WA) Ebola virus (EBOV) outbreak, severe gastrointestinal symptoms were common in patients and associated with poor outcome.
        explanation: The reference highlights that severe gastrointestinal symptoms, including diarrhea, were common and associated with poor outcomes.
  - category: Dermatologic
    name: Maculopapular Rash
    frequency: FREQUENT
    evidence:
      - reference: PMID:25780982
        supports: SUPPORT
        snippet: The main cutaneous finding of Ebola is a nonspecific maculopapular rash that appears between day four and six of disease.
        explanation: The statement is supported as the primary dermatologic phenotype associated with Ebola Virus Disease (EVD) is a nonspecific maculopapular rash, and it is noted as a main cutaneous finding.
biochemical:
  - name: Ebola Virus Antigen
    presence: Positive
    assays:
      - Antigen-Capture Enzyme-Linked Immunosorbent Assay (ELISA)
      - Reverse Transcription Polymerase Chain Reaction (RT-PCR)
    evidence:
      - reference: PMID:28573635
        supports: SUPPORT
        snippet: methods for preparing antigen detection sandwich enzyme-linked immunosorbent assays (ELISAs) for the detection of ebolavirus antigens
        explanation: This reference states that ELISA can be used for the detection of ebolavirus antigens, supporting the assertion about the Antigen-Capture Enzyme-Linked Immunosorbent Assay (ELISA).
      - reference: PMID:26874083
        supports: SUPPORT
        snippet: The diagnosis of Ebola virus disease relies on the detection of viral RNA in blood by real-time reverse-transcription PCR.
        explanation: This reference clearly states that real-time RT-PCR is used for detecting Ebola viral RNA in blood, supporting the part of the statement related to RT-PCR.
      - reference: PMID:28887479
        supports: SUPPORT
        snippet: We have developed a reduced graphene oxide-based field-effect transistor method for real-time detection of the Ebola virus antigen.
        explanation: This reference provides additional support for antigen detection methods, which indirectly supports the overall assertion.
  - name: Ebola Virus RNA
    presence: Positive
    assays:
      - Reverse Transcription Polymerase Chain Reaction (RT-PCR)
    evidence:
      - reference: PMID:26874083
        supports: SUPPORT
        snippet: The diagnosis of Ebola virus disease relies on the detection of viral RNA in blood by real-time reverse-transcription PCR.
        explanation: This reference directly supports the statement that RT-PCR assays are used to detect the presence of Ebola Virus RNA.
      - reference: PMID:26465681
        supports: SUPPORT
        snippet: 'BACKGROUND: Ebola virus has been detected in the semen of men after their recovery from Ebola virus disease (EVD)... Semen specimens obtained at baseline were tested by means of a quantitative reverse-transcriptase-polymerase-chain-reaction (RT-PCR) assay...'
        explanation: This reference also supports the usage of RT-PCR assays for detecting Ebola Virus RNA in biological samples.
environmental:
  - name: Animal Reservoirs
    notes: Fruit bats are considered the natural hosts; transmission also occurs through handling of infected wild animals.
    evidence:
      - reference: PMID:17848072
        supports: SUPPORT
        snippet: 'Among the various animals captured and analyzed, three species of fruit bats (suborder Megachiroptera) were found asymptomatically and naturally infected with Ebola virus: Hypsignathus monstrosus (hammer-headed fruit bats), Epomops franqueti (singing fruit bats), and Myonycteris torquata (little collared fruit bats).'
        explanation: This study confirms that certain species of fruit bats serve as Ebola virus reservoirs, supporting the notion that fruit bats are natural hosts of the virus.
      - reference: PMID:28573636
        supports: PARTIAL
        snippet: Although an ebolavirus natural reservoir has yet to be identified, the majority of disease ecologists believe the reservoir to belong to the order Chiroptera (bats).
        explanation: While bats are strongly suspected to be the natural reservoir, the virus has not been isolated definitively from them, providing partial but not conclusive support.
      - reference: PMID:26757869
        supports: SUPPORT
        snippet: Fruit bats are its natural reservoir, the transmission to humans is across wild animals (especially primates) and the propagation in human populations is through bodily fluid contact.
        explanation: This literature indicates that fruit bats are considered the natural reservoir for Ebola, supporting the statement.
      - reference: PMID:26310206
        supports: SUPPORT
        snippet: Ebola is not spread through the air or by water, or in general, by food. However, in Africa, Ebola may be spread as a result of handling bushmeat (wild animals hunted for food) and contact with infected bats.
        explanation: This reference supports the involvement of animal reservoirs, including fruit bats, in the transmission chain of Ebola virus.
      - reference: PMID:26147380
        supports: SUPPORT
        snippet: Ebola virus disease (EVD) is a zoonotic disease that causes severe haemorrhagic fever, with high fatality rates of up to 90% in humans.
        explanation: This reference identifies EVD as a zoonotic disease, implying the involvement of animal reservoirs.
treatments:
  - name: Supportive Care
    description: Includes rehydration, symptomatic treatment to manage fever, bleeding, and pain.
    evidence:
      - reference: PMID:37355146
        supports: SUPPORT
        snippet: Early detection and supportive care can enhance the likelihood of survival. This includes intravenous fluids, electrolyte replacement, and treatment of secondary infections.
        explanation: The provided literature supports that supportive care, including rehydration and symptomatic treatment, is a key component in the treatment of Ebola Virus Disease (EVD).
      - reference: PMID:28646340
        supports: SUPPORT
        snippet: Clinical management of EVD combines supportive and symptomatic care while also addressing the patient's emotional and mental health needs.
        explanation: This literature indicates the combination of supportive and symptomatic care is part of the clinical management of EVD.
      - reference: PMID:29054555
        supports: SUPPORT
        snippet: Key recommendations include administration of oral and, as necessary, intravenous hydration; systematic monitoring of vital signs and volume status; availability of key biochemical testing; adequate staffing ratios; and availability of analgesics, including opioids, for pain relief.
        explanation: The evidence-based guidelines for supportive care of patients with EVD include recommendations that align with rehydration and symptomatic treatments for managing fever, bleeding, and pain.
  - name: Experimental Therapies
    description: Includes antiviral drugs, immune therapies, and blood products from survivors containing antibodies.
    evidence:
      - reference: PMID:27337455
        supports: SUPPORT
        snippet: The armamentarium against EVD eventually included biologics such as monoclonal antibodies, convalescent plasma, and vaccines as well as small molecule therapeutics such as small interfering RNAs and nucleoside analogs.
        explanation: The reference mentions the use of various experimental therapies including immune therapies (monoclonal antibodies), blood products (convalescent plasma), and small molecule therapeutics (antiviral drugs).
      - reference: PMID:11766882
        supports: SUPPORT
        snippet: This review describes Ebola viruses, with a particular focus on the status of research efforts to develop vaccines and therapeutics and to identify the immune mechanisms of protection.
        explanation: The reference highlights the ongoing research for developing therapeutics, including immune mechanisms for protection, which aligns with the statement.
      - reference: PMID:25457751
        supports: SUPPORT
        snippet: Recently, the use of convalescent blood products was proposed by the WHO as one early option for treating patients with Ebola virus disease.
        explanation: The reference confirms the use of convalescent blood products as a treatment strategy for EVD, supporting the statement.
      - reference: PMID:32487785
        supports: SUPPORT
        snippet: 'Management of patients involves supportive care such as maintaining fluid along with electrolyte balance, blood pressure and oxygen saturation. This also includes treating complications arising from secondary infections. The main options include: prophylactic strategies, anti-viral therapy for EVD, immunotherapies, vaccines, and ZMapp.'
        explanation: The reference lists anti-viral therapy and immunotherapies as main treatment options, confirming the statement's reference to experimental therapies.
      - reference: PMID:30943399
        supports: SUPPORT
        snippet: We describe therapeutic monoclonal antibodies isolated from human volunteers vaccinated with recombinant adenovirus expressing Ebola virus glycoprotein (EBOV GP).
        explanation: The reference discusses therapeutic monoclonal antibodies, which are a form of immune therapy, in line with the statement.
  - name: Vaccination
    description: The rVSV-ZEBOV vaccine has been shown to be effective in preventing Ebola infection.
    evidence:
      - reference: PMID:28017403
        supports: SUPPORT
        snippet: The results add weight to the interim assessment that rVSV-ZEBOV offers substantial protection against Ebola virus disease, with no cases among vaccinated individuals from day 10 after vaccination in both randomised and non-randomised clusters.
        explanation: The study shows that rVSV-ZEBOV vaccine offers substantial protection against Ebola virus disease, supporting the statement that it is effective in preventing Ebola infection.
      - reference: PMID:32243796
        supports: SUPPORT
        snippet: Ervebo is the first licensed vaccine for prevention of Ebola virus disease.
        explanation: The article states that Ervebo (rVSV-ZEBOV) is licensed for the prevention of Ebola virus disease, supporting the statement that the vaccine is effective in preventing Ebola infection.
      - reference: PMID:33873076
        supports: SUPPORT
        snippet: 'Currently, two vaccines: Ervebo (rVSV-ZEBOV) and a two-dose combination of Zabdeno (Ad26.ZEBOV) and Mvabea (MVA-BN-Filo) have been licensed and in use.'
        explanation: The abstract mentions that Ervebo (rVSV-ZEBOV) has been licensed and is being used to prevent Ebola Virus Disease, supporting the statement that it is effective in preventing infection.
      - reference: PMID:34749265
        supports: SUPPORT
        snippet: In 2019, the FDA-approved the first anti-EBOV vaccine, rVSV-EBOV-GP (Ervebo(R) by Merck). This live-recombinant vaccine confers both prophylactic and therapeutic protection to nonhuman primates and humans.
        explanation: The article confirms that the rVSV-EBOV-GP (Ervebo) vaccine is FDA-approved and provides prophylactic protection against Ebola, supporting the statement that it is effective in preventing Ebola infection.
